What changed
The existing FDI policy for pharmaceuticals continues, but with a new condition: non-compete clauses are prohibited unless the Foreign Investment Promotion Board (FIPB) approves them in special circumstances. This change applies immediately from the circular date, April 21, 2014, and has been formalised through an amendment to FEMA regulations.
What it means for you
For banks handling FDI remittances in pharma, brownfield deals now carry extra compliance: any non-compete clause must be flagged for FIPB approval. This reduces flexibility for acquirers and may slow deal closures. Lenders must verify that no unapproved non-compete clauses exist in transaction documents before processing payments.
What you must do
- Update internal FDI processing checklists to include verification of non-compete clauses in brownfield pharma deals.
- Advise customers that non-compete clauses require prior FIPB approval; reject remittances without such approval.
- Train forex staff on the revised FEMA Notification No. FEMA.296/2014-RB dated March 3, 2014.
- Review existing brownfield pharma FDI cases to ensure compliance with the new condition.
Who it affects
AD Category-I banks processing pharma FDI, Pharmaceutical companies seeking brownfield FDI, Foreign investors in Indian pharma sector, FIPB (Foreign Investment Promotion Board)
Does this circular change the overall FDI limits for pharma?
No. The 100% automatic route for greenfield and 100% government approval route for brownfield investments remain unchanged. Only the non-compete clause condition is new.
What happens if a non-compete clause is included without FIPB approval?
Such clauses are not allowed. Banks must not process the FDI remittance unless FIPB approval for the non-compete clause is obtained. The circular makes this a mandatory condition.
Which FEMA notification implements this change?
The Foreign Exchange Management (Transfer or Issue of Security by a Person Resident outside India) (Amendment) Regulations, 2014, notified via Notification No. FEMA.296/2014-RB dated March 3, 2014.